Previous close | 72.36 |
Open | 72.36 |
Bid | 66.25 |
Ask | 68.95 |
Strike | 250.00 |
Expiry date | 2024-10-18 |
Day's range | 72.36 - 72.36 |
Contract range | N/A |
Volume | |
Open interest | 15 |
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verificatio